Effects of GHRP-2 test on hormone secretion kinetics

JRCT ID: jRCT1031230664

Registered date:28/02/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Adult growth hormone deficiency
• Date of first enrollment: 20/02/2024
• Target sample size: 50
• Study type: Observational
• Intervention(s): None

Outcome(s)

• Primary Outcome: Comparing the values of glucose metabolism-related hormones (GH, ACTH, cortisol, insulin, glucagon, GLP-1, GIP, and blood glucose levels) before and after GHRP-2 loading

Secondary Outcome

The amount of change in GH levels before and after GHRP-2 administration and the amount of each hormone related to glucose metabolism (GH, ACTH, cortisol, insulin, glucagon, GLP-1, GIP, and blood glucose) will be compared for each disease.
To verify whether there is a correlation between the change in GH levels before and after GHRP-2 administration and each hormone related to glucose metabolism (GH, ACTH, cortisol, insulin, glucagon, GLP-1, GIP, and blood glucose levels).
To examine whether there is a correlation between the change in ACTH levels before and after GHRP-2 administration and each hormone related to glucose metabolism (GH, ACTH, cortisol, insulin, glucagon, GLP-1, GIP, and blood glucose levels).
To examine whether there is a correlation between the change in cortisol levels before and after GHRP-2 administration and each hormone related to glucose metabolism (GH, ACTH, cortisol, insulin, glucagon, GLP-1, GIP, and blood glucose levels).
To examine whether there is a correlation between the change in blood glucose levels before and after GHRP-2 administration and each hormone related to glucose metabolism (GH, ACTH, cortisol, insulin, glucagon, GLP-1, GIP, and blood glucose levels).

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Patients with suspected adult growth hormone deficiency who will receive GHRP-2 at Kitasato University Hospital from the date of approval by the head of the research institute to September 30, 2026.

Exclude criteria

1) severe obesity (BMI 35 kg/m2 or more)
2) Patients under 18 years old (not intended for pediatric patients)
3) Patients with contraindications to GHRP-2 (GHRP-100 for Injection)
4) Diabetes mellitus

Related Information

• Primary Sponsor: Taguchi Tomomi